Brief: Glenmark Pharma Posts Q3 Consol Net Profit 4.03 Billion Rupees
30/01/2026 14:38
Jan 30 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: GLENMARK PHARMA Q3 CONSOL NET PROFIT 4.03 BILLION RUPEES GLENMARK PHARMA Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 39.01 BILLION RUPEES Source text: [ID:] Further company coverage: GLEN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter